Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System
Open Access
- 24 June 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Abstract
Azole antifungal drugs are commonly used to treat vulvovaginal candidiasis (VVC). The nephrotoxicity and developmental toxicity of azole drugs have not been systematically analyzed in the real world. We used the FDA Adverse Event Reporting System (FAERS) to investigate the adverse events (AEs) associated with imidazole therapy for VVC. FAERS data (from quarter 1 2004 to quarter 3 2022) were retrieved using OpenVigil 2.1, and AEs were retrieved and standardized according to the Medical Dictionary for Regulatory Activities (MedDRA). In the top 10 System Organ Class (SOC), all four drugs have been found to have kidney and urinary system diseases and pregnancy. We found significant signals, including clotrimazole [bladder transitional cell carcinoma, (report odds ratio, ROR = 291.66)], [fetal death, (ROR = 10.28)], ketoconazole[nephrogenic anemia (ROR = 22.1)], [premature rupture of membranes (ROR = 22.91 46.45, 11, 3)], Miconazole[hematuria (ROR = 19.03)], [neonatal sepsis (ROR = 123.71)], [spontaneous abortion (ROR = 5.98)], Econazole [acute kidney injury (ROR = 4.41)], [spontaneous abortion (ROR = 19.62)]. We also discovered new adverse reactions that were not reported. Therefore, when using imidazole drugs for treatment, it is necessary to closely monitor the patient's renal function, pay attention to the developmental toxicity of the fetus during pregnancy, and be aware of potential adverse reactions that may occur.Keywords
Funding Information
- Clinical Toxicology of Chinese Society of Toxicology (CST2021CT101)
This publication has 32 references indexed in Scilit:
- Author’s Reply to Joerg Putzke et al. Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”BioDrugs, 2021
- Comparison of Signal Detection Algorithms Based on Frequency Statistical Model for Drug-Drug Interaction Using Spontaneous Reporting SystemsPharmaceutical Research, 2020
- Azole resistance mechanisms in Aspergillus: update and recent advancesInternational Journal of Antimicrobial Agents, 2020
- Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance–Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseCNS Drugs, 2019
- Antidepressants-related cardiovascular adverse events using the adverse event reporting systemPsychiatry Research, 2018
- Tafenoquine for malaria prophylaxis in adults: An integrated safety analysisTravel Medicine and Infectious Disease, 2017
- Comprehensive Review in Current Developments of Imidazole-Based Medicinal ChemistryMedicinal Research Reviews, 2013
- Importance of Candida–bacterial polymicrobial biofilms in diseaseTrends in Microbiology, 2011
- Rates of Spontaneous Reporting of Adverse Drug Reactions in FranceJAMA, 2002
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reportsPharmacoepidemiology and Drug Safety, 2001